The estimated Net Worth of Tadataka Yamada is at least $91.4 Миллион dollars as of 3 March 2020. Tadataka Yamada owns over 6,500 units of Agilent Technologies stock worth over $91,007,866 and over the last 14 years he sold A stock worth over $0. In addition, he makes $351,486 as Independent Director at Agilent Technologies.
Sign up
Tadataka Yamada A stock SEC Form 4 insiders trading
Tadataka has made over 1 trades of the Agilent Technologies stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 6,500 units of A stock worth $117,000 on 3 March 2020.
The largest trade he's ever made was buying 6,500 units of Agilent Technologies stock on 3 March 2020 worth over $117,000. On average, Tadataka trades about 342 units every 0 days since 2011. As of 3 March 2020 he still owns at least 656,149 units of Agilent Technologies stock.
You can see the complete history of Tadataka Yamada stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Tadataka Yamada biography
Dr. Tadataka Yamada M.D. serves as Independent Director of the Company. Dr. Yamada is the Co-Founder and Chairperson of the Board of Directors of Phathom Pharmaceuticals, Inc., which was founded in 2018. He is currently a Venture Partner on the Life Sciences team of Frazier Healthcare Partners, a healthcare-focused investment firm. From June 2011 to June 2015, Dr. Yamada served as the Chief Medical and Scientific Officer of Takeda Pharmaceuticals International, Inc., a research-based global pharmaceutical company. Dr. Yamada previously served as President of the Global Health Program of the Bill & Melinda Gates Foundation from June 2006 to June 2011. From 2000 to 2006, Dr. Yamada was Chairperson of Research and Development for GlaxoSmithKline Inc. and prior to that, he held research and development positions at SmithKline Beecham. Prior to joining SmithKline Beecham, Dr. Yamada was Chairperson of the Department of Internal Medicine at the University of Michigan Medical School and Physician-in-Chief of the University of Michigan Medical Center.
What is the salary of Tadataka Yamada?
As the Independent Director of Agilent Technologies, the total compensation of Tadataka Yamada at Agilent Technologies is $351,486. There are 11 executives at Agilent Technologies getting paid more, with Michael McMullen having the highest compensation of $12,520,600.
How old is Tadataka Yamada?
Tadataka Yamada is 75, he's been the Independent Director of Agilent Technologies since 2011. There are no older and 25 younger executives at Agilent Technologies.
What's Tadataka Yamada's mailing address?
Tadataka's mailing address filed with the SEC is C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA, 98011.
Insiders trading at Agilent Technologies
Over the last 22 years, insiders at Agilent Technologies have traded over $170,735,833 worth of Agilent Technologies stock and bought 25,786 units worth $823,096 . The most active insiders traders include William P Sullivan, George A Scangos и Mikael Dolsten. On average, Agilent Technologies executives and independent directors trade stock every 20 days with the average trade being worth of $3,748,368. The most recent stock trade was executed by Padraig Mcdonnell on 22 August 2024, trading 1,958 units of A stock currently worth $283,910.
What does Agilent Technologies do?
analytical scientists and clinical researchers worldwide rely on agilent to help fulfill their most complex laboratory demands. our instruments, software, services and consumables address the full range of scientific and laboratory management needs—so our customers can do what they do best: improve the world around us. whether a laboratory is engaged in environmental testing, academic research, medical diagnostics, pharmaceuticals, petrochemicals or food testing, agilent provides laboratory solutions to meet their full spectrum of needs. we work closely with customers to help address global trends that impact human health and the environment, and to anticipate future scientific needs. our solutions improve the efficiency of the entire laboratory, from sample prep to data interpretation and management. customers trust agilent for solutions that enable insights...for a better world.
What does Agilent Technologies's logo look like?
Complete history of Tadataka Yamada stock trades at Agilent Technologies, Phathom Pharmaceuticals Inc, Passage Bio Inc и Athira Pharma
Agilent Technologies executives and stock owners
Agilent Technologies executives and other stock owners filed with the SEC include:
-
Michael McMullen,
President, Chief Executive Officer, Director -
Robert McMahon,
Chief Financial Officer, Senior Vice President -
Jacob Thaysen,
Senior Vice President, President - Life Sciences and Applied Markets Group -
Michael R. McMullen,
CEO, Pres & Director -
Michael Tang,
Senior Vice President, General Counsel, Secretary -
Robert W. McMahon,
Sr. VP & CFO -
Jacob Thaysen,
Sr. VP and Pres of Life Sciences & Applied Markets Group -
Michael Tang,
Sr. VP, Gen. Counsel & Sec. -
Samraat S. Raha,
Sr. VP and Pres of Diagnostics & Genomics Group -
Boon Hwee Koh,
Non-Executive Independent Chairman of the Board -
Paul Clark,
Independent Director -
Tadataka Yamada,
Independent Director -
Dow Wilson,
Independent Director -
Sue Rataj,
Independent Director -
Daniel Podolsky,
Independent Director -
George Scangos,
Independent Director -
Heidi Kunz,
Independent Director -
Hans Bishop,
Independent Director -
Mala Anand,
Independent Director -
Dominique Grau,
Senior Vice President - Human Resources -
Rodney Gonsalves,
Chief Accounting Officer, Vice President, Corporate Controllership -
Samraat Raha,
Senior Vice President, President - Diagnostics and Genomics Group -
Padraig McDonnell,
Senior Vice President, President - Agilent CrossLab Group -
Henrik Ancher-Jensen,
Senior Vice President, President - Order Fulfillment -
Richard A. Burdsall,
Sr. VP of Global Infrastructure Services -
Rodney Gonsalves,
Principal Accounting Officer, VP & Corp. Controller -
Allison Ballmer,
Sr. VP of Strategy & Corp. Devel. -
Dominique P. Grau,
Sr. VP of HR & Global Communications -
Ankur Dhingra,
VP of Investor Relations -
Dr. Darlene J. S. Solomon,
CTO & Sr. VP -
Robert J Herbold,
Director -
Mark Doak,
Sr. Vice President -
James Cullen,
Director -
Heidi Fields,
Director -
Patrick Kaltenbach,
Sr Vice President -
Mikael Dolsten,
Director -
Adrian T Dillon,
Executive Vice President & CFO -
Didier Hirsch,
Vice President & Controller -
Lonnie G. Justice,
Vice President -
Saleem N. Odeh,
Vice President -
David S Churchill,
Vice President -
Robert L Joss,
Director -
Soon Chai Gooi,
Vice President -
D Craig Nordlund,
Sr VP, General Counsel & Sec. -
Thomas White,
Senior Vice President -
Walter B Hewlett,
Director -
Edward W Barnholt,
President, CEO, and Chairman -
Ingen Chris Van,
Senior Vice President -
Young Sohn,
Senior Vice President -
Dick M Chang,
Senior Vice President -
Jack P Trautman,
Senior Vice President -
David B Jr Cooper,
Senior Vice President -
Patrick J Byrne,
Senior Vice President -
Marie Oh Huber,
Sr VP, General Counsel & Sec. -
William P Sullivan,
EVP & Chief Operating Officer -
A Barry Rand,
Director -
Solange Glaize,
VP, Chief Accounting Officer -
Fred Strohmeier,
Senior Vice President -
David M Lawrence,
Director -
Guy Sene,
Senior Vice President -
Lars Holmkvist,
Senior Vice President -
Ronald S. Nersesian,
Vice President -
Jean Mcclung Nye,
Senior Vice President -
Nicolas H Phd Roelofs,
Vice President -
Simon May,
Senior Vice President -
Otis W Brawley,
Director -
Philip Binns,
Senior Vice President -
Angelica Riemann,
Senior Vice President -
Bret Di Marco,
Senior Vice President